Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Post by The300on Dec 09, 2010 12:49pm
449 Views
Post# 17824338

Our next move up

Our next move upWith the private placement now out in the open, it looks like we have renewed confidence in the stock from long term shareholders, including myself, and have likely hit the radars of a few new investors and institutions.

It looks like the stock is starting to consolidate in the $.50 cent range, which I believe is fair given where we were 2 months ago.  As pointed out by another poster, I appreciate the fact that the money being raised is hard dollars and not flow through.  A $.50 flow through financing would have been very detrimental to the stock price.  One point which I did find curious was that the Hudbay private placement was contingent on Halo raising $2.2 million of their own accord.  Not quite sure as to the rationale there and would welcome any insight.

Now, on to my thoughts about our next move up.  As much as I would love to see a gap up before the year is out, I don't think it is likely (barring any major news).  I believe that Halo will be trading in the range of $.48 to $.58.  I think the reason for this holding pattern will be selling coming from those trying to sell their shares on the open market in order to participate in the current private placement.  Once again, it is just a part of the process and has nothing to do with the fundamentals.  Once the private placement has been closed, then we continue to move our way up.

I remain very confident in this company as the insitu values (and  I'm only refering to those that we know of via the resource estimate) are being given a considerable discout when looking at our market cap.  Now, throw in the blue sky potential for the rest of the Sherridon package (and I believe that there is an elephant out there waiting to be found) and you have alot of upside with minimal downside at $.50.  And I didn't even touch on the Red Lake exploration or the cash flow which will be generated from the Bachelor Lake Mine NSR  which I believe will be generating between $50,000 and $60,000 per month starting early next year. 

As always, the above is only my humble opinion.

The 300 (Molon Lave)
<< Previous
Bullboard Posts
Next >>